lupus and glp 1 Risk of End-Stage Renal Disease Among Patients with Nephritis on GLP-1 Receptor Agonists: A Retrospective Cohort Study GLP-1s reduce mortality in lupus

Rate of inactive IIH was not associated with the treatment group but with the papilledema degree at baseline (M3: \(\beta\)=0.38, 95% CI 0.20, 0.57

Patients should maintain consistent timing of levothyroxine administration and report any symptoms suggesting altered thyroid status, prompting laboratory reassessment

Consult with a Healthcare Provider Before starting glutathione supplementation, consult with a healthcare provider to discuss your specific health needs, potential interactions with other medications, and the appropriate dosage

Data showed that GLP-1 significantly increased PI3K, Akt, and mammalian target of rapamycin (mTOR) phosphorylation without inducing the expression of PI3K, Akt, or mTOR